Provided by Tiger Trade Technology Pte. Ltd.

ZYMEWORKS INC (US)

26.24
-0.1950-0.74%
Post-market: 26.240.00000.00%16:51 EDT
Volume:574.57K
Turnover:15.13M
Market Cap:1.86B
PE:-12.99
High:26.99
Open:26.62
Low:26.03
Close:26.44
52wk High:31.34
52wk Low:15.49
Shares:70.96M
Float Shares:66.05M
Volume Ratio:1.07
T/O Rate:0.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0200
EPS(LYR):-1.0800
ROE:-72.31%
ROA:-24.14%
PB:23.17
PE(LYR):-24.30

Loading ...

Theravance Biopharma: Co to Pay $32.5 Mln Termination Fee to Zymeworks, if Deal Terminated Under Certain Circumstances

THOMSON REUTERS
·
Jun 29

Theravance Biopharma to be acquired by Zymeworks for $17.00 per share in cash

TIPRANKS
·
Jun 29

Theravance Biopharma Shares Fall 3.3% Premarket; Co to be Acquired by Zymeworks for $17 Per Share in Cash Plus a Contingent Value Right

THOMSON REUTERS
·
Jun 29

Zymeworks to Acquire Theravance Biopharma for USD 17 Per Share in USD 929 Million Deal

Reuters
·
Jun 29

Theravance Biopharma - Strategic Review Committee and Board Unanimously Approve and Recommend Deal

THOMSON REUTERS
·
Jun 29

Theravance Biopharma - Deal Represents Equity Value of About $929 Mln

THOMSON REUTERS
·
Jun 29

Theravance Biopharma - to be Bought by Zymeworks for $17 Per Share in Cash Plus CVR

THOMSON REUTERS
·
Jun 29

Theravance Biopharma - Shareholders to Receive CVR for 80% of Net Proceeds from Ampreloxetine Monetization

THOMSON REUTERS
·
Jun 29

Zymeworks - Deal Financed by $350 Mln Non-recourse Note, $360 Mln Net Cash, $219 Mln Zymeworks Cash

THOMSON REUTERS
·
Jun 29

Zymeworks - Deal Expected to be Accretive to Earnings and Cash Flow

THOMSON REUTERS
·
Jun 29

Zymeworks - to Retain $2.5 Bln Irish Tax Attributes from Theravance Biopharma

THOMSON REUTERS
·
Jun 29

Zymeworks - Theravance Biopharma Expected to Receive $100 Mln Trelegy Ellipta Milestone in Q1 2027

THOMSON REUTERS
·
Jun 29

Zymeworks to Acquire Theravance Biopharma, Inc.

THOMSON REUTERS
·
Jun 29

Zymeworks Said to Near $929 Million Deal for Theravance - Bloomberg News

Reuters
·
Jun 29

Zymeworks is Discussing Paying $17 Per Share for Theravance- Bloomberg News

THOMSON REUTERS
·
Jun 29

ZW191’s Broad Phase 1 Activity in Ovarian Cancer Could Be A Game Changer For Zymeworks (ZYME)

Simply Wall St.
·
Jun 23

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Maze Therapeutics, Inc. (MAZE) and Universal Health (UHS)

TIPRANKS
·
Jun 22

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Amylyx Pharmaceuticals Inc (AMLX) and AbCellera Biologics (ABCL)

TIPRANKS
·
Jun 18

Zymeworks partners with Gandeeva to generate cryo-EM structural data for antibody discovery

Reuters
·
Jun 18

Zymeworks Reports Promise With Anti-Cancer Drug

MT Newswires Live
·
Jun 15